Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success
Up next
Author


Sarepta’s stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.

You May Also Like
I’m 66. My mortgage is $250K and the rate is 3.4%. Would it be foolish to pay it off from my $770K investments?

I’m 66. My mortgage is $250K and the rate is 3.4%. Would it be foolish to pay it off from my $770K investments?

“I don’t plan on taking Social Security until 70 and I will…
Intel’s CEO is about to visit Trump. What’s at stake for the chip maker in D.C.’s crosshairs.

Intel’s CEO is about to visit Trump. What’s at stake for the chip maker in D.C.’s crosshairs.

Intel’s turnaround is at risk given political criticism of CEO Lip-Bu Tan.…
Has bitcoin peaked yet? Options and futures markets are saying no.

Has bitcoin peaked yet? Options and futures markets are saying no.

Bitcoin has kept refreshing all-time highs over the past few days, leading…

‘FTX was not fine’: How Sam Bankman-Fried’s tweets became central to his trial

Sam Bankman-Fried’s tweets have come back to haunt him.  As customers raced…